PB2110: PHARMACOKINETICS AND PHARMACODYNAMICS IN FIRST-MIND: A PHASE IB, OPEN-LABEL, RANDOMIZED STUDY OF TAFASITAMAB ± LENALIDOMIDE + R-CHOP IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA

• D. Belada,
• K. Kopeckova,
• J. M. Bergua Burgues,
• D. Stevens,
• G. S. Nowakowski,
• M. Waldron-Lynch,
• N. Hadar,
• J. Weirather,
• C. Lässig,
• D. Blair,
• M. Dreyling

Affiliations

D. Belada

1 4th Department of Internal Medicine - Haematology, Charles University, Hospital and Faculty of Medicine, Hradec Králové

K. Kopeckova

2 Department of Oncology of the 2nd Faculty of Medicine, Charles University and University Hospital in Motol, Prague, Czechia

J. M. Bergua Burgues

3 Department of Hematology, Hospital San Pedro de Alcantara, Cáceres, Spain

D. Stevens

4 Norton Cancer Institute - St. Matthews Campus, 3991 Dutchmans Lane, 40207, Louisville

G. S. Nowakowski

5 Division of Hematology, Mayo Clinic, Rochester

M. Waldron-Lynch

6 MorphoSys US, Inc., Boston, United States of America

N. Hadar

6 MorphoSys US, Inc., Boston, United States of America

J. Weirather

7 MorphoSys AG, Planegg

C. Lässig

7 MorphoSys AG, Planegg

D. Blair

7 MorphoSys AG, Planegg

M. Dreyling

8 Medical Clinic III, Ludwig-Maximilians-University Hospital, Munich, Germany